Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation

Gi Yeon Han, Eun Kyung Lee, Hey Won Park, Hyun Jung Kim, Chan Wha Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Redox-regulating molecule, recombinant human thioredoxin (rhTRX) which shows anti-inflammatory, and anti-oxidative effects against lipopolysaccharide (LPS)-stimulated inflammation and regulate protein expression levels. LPS-induced reactive oxygen intermediates (ROI) and NO production were inhibited by exogenous rhTRX. We identified up/downregulated intracellular proteins under the LPS-treated condition in exogenous rhTRX-treated A375 cells compared with non-LPS-treated cells via 2-DE proteomic analysis. Also, we quantitatively measured cytokines of in vivo mouse inflammation models using cytometry bead array. Exogenous rhTRX inhibited LPS-stimulated production of ROI and NO levels. TIP47 and ATP synthase may influence the inflammation-related lipid accumulation by affecting lipid metabolism. The modulation of skin redox environments during inflammation is most likely to prevent alterations in lipid metabolism through upregulation of TIP47 and ATP synthase and downregulation of inflammatory cytokines. Our results demonstrate that exogenous rhTRX has anti-inflammatory properties and intracellular regulatory activity in vivo and in vitro. Monitoring of LPS-stimulated pro-inflammatory conditions treated with rhTRX in A375 cells could be useful for diagnosis and follow-up of inflammation reduction related with candidate proteins. These results have a therapeutic role in skin inflammation therapy.

Original languageEnglish
Article numbere71
JournalExperimental and Molecular Medicine
Volume46
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Thioredoxins
Lipopolysaccharides
Inflammation
Lipids
Lipid Metabolism
Oxidation-Reduction
Skin
Anti-Inflammatory Agents
Down-Regulation
Adenosine Triphosphate
Cytokines
Oxygen
Proteins
Proteomics
Up-Regulation
Cells
Modulation
Molecules
Monitoring
Therapeutics

Keywords

  • Inflammation
  • Lipid accumulation
  • RhTRX
  • Skin cell proteomics
  • TIP47

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation. / Han, Gi Yeon; Lee, Eun Kyung; Park, Hey Won; Kim, Hyun Jung; Kim, Chan Wha.

In: Experimental and Molecular Medicine, Vol. 46, No. 1, e71, 01.01.2014.

Research output: Contribution to journalArticle

Han, Gi Yeon ; Lee, Eun Kyung ; Park, Hey Won ; Kim, Hyun Jung ; Kim, Chan Wha. / Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation. In: Experimental and Molecular Medicine. 2014 ; Vol. 46, No. 1.
@article{c3356733b4d94da9afe11e63e5c08e85,
title = "Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation",
abstract = "Redox-regulating molecule, recombinant human thioredoxin (rhTRX) which shows anti-inflammatory, and anti-oxidative effects against lipopolysaccharide (LPS)-stimulated inflammation and regulate protein expression levels. LPS-induced reactive oxygen intermediates (ROI) and NO production were inhibited by exogenous rhTRX. We identified up/downregulated intracellular proteins under the LPS-treated condition in exogenous rhTRX-treated A375 cells compared with non-LPS-treated cells via 2-DE proteomic analysis. Also, we quantitatively measured cytokines of in vivo mouse inflammation models using cytometry bead array. Exogenous rhTRX inhibited LPS-stimulated production of ROI and NO levels. TIP47 and ATP synthase may influence the inflammation-related lipid accumulation by affecting lipid metabolism. The modulation of skin redox environments during inflammation is most likely to prevent alterations in lipid metabolism through upregulation of TIP47 and ATP synthase and downregulation of inflammatory cytokines. Our results demonstrate that exogenous rhTRX has anti-inflammatory properties and intracellular regulatory activity in vivo and in vitro. Monitoring of LPS-stimulated pro-inflammatory conditions treated with rhTRX in A375 cells could be useful for diagnosis and follow-up of inflammation reduction related with candidate proteins. These results have a therapeutic role in skin inflammation therapy.",
keywords = "Inflammation, Lipid accumulation, RhTRX, Skin cell proteomics, TIP47",
author = "Han, {Gi Yeon} and Lee, {Eun Kyung} and Park, {Hey Won} and Kim, {Hyun Jung} and Kim, {Chan Wha}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/emm.2013.136",
language = "English",
volume = "46",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "1",

}

TY - JOUR

T1 - Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation

AU - Han, Gi Yeon

AU - Lee, Eun Kyung

AU - Park, Hey Won

AU - Kim, Hyun Jung

AU - Kim, Chan Wha

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Redox-regulating molecule, recombinant human thioredoxin (rhTRX) which shows anti-inflammatory, and anti-oxidative effects against lipopolysaccharide (LPS)-stimulated inflammation and regulate protein expression levels. LPS-induced reactive oxygen intermediates (ROI) and NO production were inhibited by exogenous rhTRX. We identified up/downregulated intracellular proteins under the LPS-treated condition in exogenous rhTRX-treated A375 cells compared with non-LPS-treated cells via 2-DE proteomic analysis. Also, we quantitatively measured cytokines of in vivo mouse inflammation models using cytometry bead array. Exogenous rhTRX inhibited LPS-stimulated production of ROI and NO levels. TIP47 and ATP synthase may influence the inflammation-related lipid accumulation by affecting lipid metabolism. The modulation of skin redox environments during inflammation is most likely to prevent alterations in lipid metabolism through upregulation of TIP47 and ATP synthase and downregulation of inflammatory cytokines. Our results demonstrate that exogenous rhTRX has anti-inflammatory properties and intracellular regulatory activity in vivo and in vitro. Monitoring of LPS-stimulated pro-inflammatory conditions treated with rhTRX in A375 cells could be useful for diagnosis and follow-up of inflammation reduction related with candidate proteins. These results have a therapeutic role in skin inflammation therapy.

AB - Redox-regulating molecule, recombinant human thioredoxin (rhTRX) which shows anti-inflammatory, and anti-oxidative effects against lipopolysaccharide (LPS)-stimulated inflammation and regulate protein expression levels. LPS-induced reactive oxygen intermediates (ROI) and NO production were inhibited by exogenous rhTRX. We identified up/downregulated intracellular proteins under the LPS-treated condition in exogenous rhTRX-treated A375 cells compared with non-LPS-treated cells via 2-DE proteomic analysis. Also, we quantitatively measured cytokines of in vivo mouse inflammation models using cytometry bead array. Exogenous rhTRX inhibited LPS-stimulated production of ROI and NO levels. TIP47 and ATP synthase may influence the inflammation-related lipid accumulation by affecting lipid metabolism. The modulation of skin redox environments during inflammation is most likely to prevent alterations in lipid metabolism through upregulation of TIP47 and ATP synthase and downregulation of inflammatory cytokines. Our results demonstrate that exogenous rhTRX has anti-inflammatory properties and intracellular regulatory activity in vivo and in vitro. Monitoring of LPS-stimulated pro-inflammatory conditions treated with rhTRX in A375 cells could be useful for diagnosis and follow-up of inflammation reduction related with candidate proteins. These results have a therapeutic role in skin inflammation therapy.

KW - Inflammation

KW - Lipid accumulation

KW - RhTRX

KW - Skin cell proteomics

KW - TIP47

UR - http://www.scopus.com/inward/record.url?scp=84896879407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896879407&partnerID=8YFLogxK

U2 - 10.1038/emm.2013.136

DO - 10.1038/emm.2013.136

M3 - Article

C2 - 24406320

AN - SCOPUS:84896879407

VL - 46

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 1

M1 - e71

ER -